Our very own Senior Manager of Medical Content, Becky Campbell, sat down with Dr. Martin Schoen MD MPH to discuss the increase in survival rates among veterans VA Research and the general population diagnosed with metastatic #prostatecancer .

9/10
Our clinicians know Veterans—they often are Veterans—and they know exactly how to help. Even if you don’t need this care today, you might need it tomorrow, or the next day, or 30 years from now. It’s quick and easy to apply, and once you’re in, you have access for life.

Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 Herbert Irving Comprehensive Cancer Center (led by George Mellgard)- Now out in HemaSphere Journal (IF = 9.1)!
#mmsm 🧵
onlinelibrary.wiley.com/doi/10.1002/he…

Withdrawn | Cancer Accelerated Approvals. There are 28 drugs. That is why we need to be careful of how we interpret data from drugs based on accelerated approval. fda.gov/drugs/resource…

Here is the power of health equity in VA: a new study suggests that among prostate cancer patients, VA health care is better at mitigating the social disparities usually associated with poor health outcomes. jamanetwork.com/journals/jaman…

👏Congrats to Isla Garraway, MD, PhD et al for this work in JAMA Network Open

For #prostatecancer pts in Cali ☀️🌴

🏥Treatment at VA (= access) vs Non-VA (≠ access) healthcare systems

VA ➡️ decreases📉 in racial & socioeconomic disparities in cancer outcomes

Link:

🚨New US data in JAMA Network Open

Median OS for patients w/ metastatic #prostatecancer Dx'ed 2000-2004 v 2015-2019

Gen pop.: 📈23.0➡️30.0 mo
VA pop.: 📈25.6➡️30.9 mo

Improved Tx's definitely playing a role & likely some stage migration w/ PET

Link: tinyurl.com/3jwc9p3c

The SLiM criteria are repeatedly mentioned without any mention of how they have not aged well.

The diagnosis of myeloma was changed in 2014 because we used to think having these SLiM criteria portended an 80% risk of progression to CRAB myeloma.

The reality is that its 30%!

Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer geriatriconcology.net/article/S1879-… Tanya Wildes MD William Dale, MD, PhD, FASCO Supriya Mohile Cancer and Aging Research Group (CARG) #GeriOnc #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Frailty #Efficacy

'Memorial Sloan Kettering Study Exposes $43 Million Medicare Overspend on Cancer Drug Denosumab'

Someone once told me that what I do is 'kind of like investigative journalism, with data'

I thought the title of this article fits well with that!

medriva.com/health/memoria…

An article recently published in JAMA reported that Veterans have a higher likelihood of dying if they choose care in the community rather than at the VA. This article summarizes its findings, emphasizing the lack of oversight outside the VA, influence of politicians, and more.

Repeat after me:

Subsequent therapies do not CONFOUND overall survival.

Appropriate subsequent therapies should be given! Any analysis that adjusts for them is meaningless (you want your results to apply to a world where subsequent treatment is given!)

pubmed.ncbi.nlm.nih.gov/38426294/

Hospitalizations among #veterans treated for metastatic #ProstateCancer with abiraterone or enzalutamide. #BeyondTheAbstract with Martin Schoen MD MPH, key findings point to potential differences in adverse events. #ReadNow on UroToday > bit.ly/3SEjuMp

mHSCP, PSA <0.2 at 6months, patients live a long time regardless of therapy #usanz2024 Christopher Sweeney, MBBS

Our meta-analysis evaluating impact of ARSI therapy for #prostatecancer on falls & fractures 🦴 finally out in European Urology Oncology

Link: authors.elsevier.com/sd/article/S25…

Craig Jones Struan Gray Mick Brown 🇮🇳 Bhavan Rai 🇬🇧

GU Cancer Research group Division of Cancer Sciences

Equal Censoring But Still Informative: When The Reasons For Censoring Differ Between Treatment Arms
European Journal of cancer
doi.org/10.1016/j.ejca…
🧐Food for thoughts...
👉Reasons for censoring should be more clearly reported
ESMO - Eur. Oncology

Aaron Goodman - “Papa Heme” The only card ABIM has left to play is that medical centers often require this certification. Academic leaders, now is your time to lead. Let these doctors practice.